Indivior is pioneering the development and discovery of treatment strategies for opioid use disorder and other substance use disorders.
Indivior’s R&D has led to a range of daily and monthly treatment options for patients with moderate-to -severe opioid use disorder.
To learn more about our commercially launched products, please visit the products page.
Brand Name/Product Candidate
Preclinical
Phase 1
Phase 2
Phase 3
Regulatory Approval
Commercial Launch
-
Treatment of Opioid Use Disorder
INDV-6001* is a sustained-release LAI prodrug of buprenorphine
-
Treatment for Opioid Use Disorder
INDV-2000 selective orexin-1 receptor antagonist
-
Treatment for Alcohol Use Disorder
INDV-1000** Gamma-aminobutyric acid subtype B (GABAB) positive allosteric modulator (PAM)
